Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

By sjmartinez • May 15, 2024

Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman G, Caskey M, Hughes MD, Smith DM, Eron JJ; ACTIV-2/A5401 Study Team. Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial. Pathog Immun. 2024 May 6;9(1):138-155. doi: 10.20411/pai.v9i1.660. PMID: 38746756; PMCID: PMC11093219.

Tags: covid-19, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, outpatient treatment, Publications, SARS-CoV-2, subcutaneous

Development of a Primary Care Cardio-Kidney Risk Navigator for Clinical Decision Support

Gluckman TJ, Birkeland K, Bhatt A, Budoff MJ, Danna SC, Desai NR, Norfolk E, Elbedewe A, Kiernan G, Pachpor R, Hirsch J. Development of a[...]

Predictive Value of Coronary Artery Calcium Score From Nongated Chest CT Scans Compared With Gated Scans and Incidence of Cardiovascular Events

Verghese D, Trujillo R, Abraham D, McClelland RL, Kinninger A, Manubolu S, Aldana J, Cubeddu RJ, Drachman D, Inglessis-Azuaje I, Wang DD, Fahed A, Brumback[...]

Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 35 Trials including 114 592 Individuals

Abuknesha NR, O'Keefe JH, Qian F, Tintle NL, Lin Y, Sun Y, Qian HZ, Aisen PS, Albert CM, Aronson WJ, Asbeutah AAA, Bischoff-Ferrari HA, Budoff[...]